Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

被引：0
|
作者：
Wang, Zongren [1 ]
Zhan, Wenhao [1 ]
Huang, Bin [1 ]
Luo, Cheng [1 ]
Chen, Lingwu [1 ]
Chen, Junxing [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-226-9326; 613-135-2370-7650-2454; 613-4678-146-11576; 613-135-244-3829; 6; 5; 4; 3; 2; 158; 2424; 1714; 76; 62; 1; 38092-20390; 38092-29187;
D O I：
10.1200/JCO.2024.42.4_suppl.618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [1] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] The Effectiveness of Bacillus Calmette-Guerin (BCG) Maintenance Treatment in Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Kim, B.
    Ha, J.
    Park, C.
    Kim, C.
    UROLOGY, 2012, 80 (03) : S215 - S216
  • [4] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [5] Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer
    Zaza, Mohamed Mahmoud Abdelfatah
    Salem, Tarek Abd El-Mageed
    El-Sadat, Ahmed Mohamed
    Ali, Mohammed Hassan
    UROLOGIA JOURNAL, 2024, 91 (01) : 61 - 68
  • [6] Intravesical bacillus Calmette-Guerin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer
    Ekin, Rahmi Gokhan
    Akarken, Ilker
    Zorlu, Ferruh
    Tarhan, Huseyin
    Kucuk, Ulku
    Yildirim, Zubeyde
    Divrik, Rauf Taner
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (5-6): : E278 - E283
  • [7] Bacillus Calmette-Guerin Without Maintenance Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    Herr, Harry W.
    Dalbagni, Guido
    Donat, Sherri M.
    EUROPEAN UROLOGY, 2011, 60 (01) : 32 - 36
  • [8] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [9] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUERIN (BCG)UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
    Siamak, Daneshmand
    Daniel, Zainfeld
    Christopher, Pieczonka
    Giuseppe, Simone
    Michiel, S. van der Heijden
    Martin, Bogemann
    David, S. Morris
    Philipp, Spiegelhalder
    Laurence, H. Belkoff
    Karel, Decaestecker
    Harm, Arentsen
    Shalaka, Hampras
    Christopher, J. Cutie
    Hussein, Sweiti
    Katharine, Stromberg
    Jason, Martin
    Abhijit, Shukla
    Joseph, M. Jacob
    Evanguelos, Xylinas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
12345